Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french associationAdriana Pleșa, Christophe Roumier, Alexandra Coelho et al.|Blood|2025Cited by 1
Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.Jean-Baptiste Micol, Elsa Bernard, Emmanuel Raffoux et al.|Blood|2025Cited by 1
IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AMLMohamad Sabbah, Raphaël Itzykson, Morgane Fontaine et al.|Blood|2024Cited by 0
Real-world patterns of treatment intensity and prognostic model performance in older AML: Insights from the french ALFA-PPP cohortLin-Pierre Zhao, Lionel Adès, Céline Berthon et al.|Blood|2025Cited by 0
Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP CohortLin‐Pierre Zhao, Lionel Adès, Céline Berthon et al.|Leukemia|2026Cited by 0